MADRIGAL PHARMACEUTICALS, INC. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Madrigal reported Q2 2026 Rezdiffra net sales of $364.3 million (71% YoY growth) with 49,000+ patients on therapy as of June 30, 2026. The company strengthened IP with 3 new resmetirom patents (F2-F3 dosing/rosuvastatin combo, F4c cirrhosis treatment, protection through 2042–2045) and initiated Phase 1 dosing of MGL-2086 (oral GLP-1) in June 2026 for combination MASH therapy. Cash position: $838.9 million as of June 30, 2026 (down from $988.6 million at year-end 2025); Q2 net loss was $57.9 million ($1.99/share) vs. $42.3 million prior year, including $25 million one-time business development expenses.
Why this rating
Strong revenue growth (71% YoY) and patient adoption (49K+) demonstrate strong market traction; IP strength extends exclusivity; pipeline advancement supports long-term positioning. Modest significance relative to $5.6B market cap—event is positive but within market expectations for established product.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.